Core Viewpoint - Chengdu Easton Biopharmaceuticals Co., Ltd. reported a decrease in revenue and net profit for the first half of 2025, primarily due to the impact of national centralized procurement policies and increased equity incentive expenses, while maintaining a strong focus on innovation and product development in the pharmaceutical industry. Financial Performance - The company achieved operating revenue of CNY 654.45 million, a decrease of 2.25% compared to the same period last year [3] - Total profit amounted to CNY 149.74 million, down 6.10% year-on-year [3] - Net profit attributable to shareholders was CNY 136.57 million, a decline of 6.77% compared to the previous year [3] - The net cash flow from operating activities increased significantly by 83.16% to CNY 157.47 million [3] - The company's net assets reached CNY 2.78 billion, reflecting a growth of 3.05% from the end of the previous year [3] Business Overview - The company operates as a high-tech enterprise focusing on the research, development, production, and sales of chemical raw materials, high-end chemical drugs, and biological drugs [5] - It has successfully industrialized 66 high-end chemical drugs, including 8 domestic first-generic products and 57 that have passed consistency evaluations [5][14] - The company is actively engaged in the development of over 10 first-class new drugs and has a robust pipeline in the anesthetic and analgesic fields [5][14] Industry Context - The pharmaceutical manufacturing industry in China is transitioning from rapid growth to high-quality development, emphasizing the need for innovation and improved product quality [10][19] - The industry faces challenges such as low concentration, insufficient original innovation capabilities, and strong international competition in high-value products [12] - The demand for generic drugs remains significant due to the aging population and the increasing prevalence of chronic diseases, while innovative drugs are essential for addressing unmet clinical needs [11][19] Innovation and R&D - The company has increased its R&D investment, with R&D expenses accounting for 20.25% of operating revenue, up from 18.27% in the previous year [3][15] - It focuses on developing high-barrier, high-technical-difficulty generic drugs while accelerating the transition from generics to innovative drugs [5][15] - The company is enhancing its capabilities in antibody technology and bioconjugation technology, targeting oncology, anesthetic analgesia, and immune diseases [7][15] Market Position - The company holds a leading market share in the anesthetic and analgesic sectors, with 18 products launched and over 20 in development [14] - It has established a competitive advantage through a diverse product pipeline and strong market presence in chronic disease treatment [14][19] - The company has received multiple honors and recognitions, including being named a national high-tech enterprise and receiving various awards for its innovation and R&D capabilities [16][19]

成都苑东生物制药股份有限公司2025 年半年度报告摘要 公司代码：688513 公司简称：苑东生物 成都苑东生物制药股份有限公司 成都苑东生物制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅第三节"管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注，注意投资风险。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 上海证券交易所科 A股 苑东生物 688513 不适用 创板 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书 证券事务代表 姓名 李淑云 张敏 电话 028-86106668 028-86106668 办公地址 成都市双流区安康路8号 成都市双流区安康路8号 电子信箱 ydsw@eastonpharma.cn y ...

Meeting Overview - The fourth board meeting of Chengdu Yuandong Biopharmaceutical Co., Ltd. was held on August 18, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the half-year report and its summary for 2025, with a unanimous vote of 9 in favor [2][3]. - The board also approved a special report on the management and actual use of raised funds for the first half of 2025, confirming compliance with legal requirements and proper decision-making procedures [2][3]. - A report on the mid-year evaluation of the "Quality Improvement and Efficiency Recovery Action Plan for 2025" was also approved unanimously [3]. - The board agreed to postpone certain fundraising investment projects, stating that the decision was made based on practical circumstances and would not adversely affect normal operations [3][4]. - An agreement related to the production information system with a related party was approved, emphasizing the necessity of digital and intelligent management in the pharmaceutical industry [4].

证券代码：688513 证券简称：苑东生物 公告编号：2025-058 成都苑东生物制药股份有限公司 二、 监事会会议审议情况 经审议，会议以投票表决的方式通过以下议案： （一）审议通过《关于 <公司 ensp="ensp" 年半年度报告及其摘要="年半年度报告及其摘要"> 的议 案》 监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序符合相关 法律法规及《公司章程》等内部规章制度的规定，其内容与格式符合中国证监会 和上海证券交易所的各项规定，公允地反映了公司 2025 年半年度的财务状况和 经营成果等事项。 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 成都苑东生物制药股份有限公司（以下简称"公司"）第四届监事会第六次会 议于 2025 年 8 月 18 日在公司会议室以现场形式召开。会议通知已于 2025 年 8 月 8 日以电话通知、电子邮件等方式送达全体监事。本次会议应出席监事 3 名， 实际出席监事 3 名，本次会议由监事会主席罗雯婕女士主 ...

报告期内，公司未发生用闲置募集资金暂时补充流动资金情况。 成都苑东生物制药股份有限公司 专项报告 成都苑东生物制药股份有限公司（以下简称"苑东生物"、"本公司"或"公司"） 董事会根据《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规 范运作》及相关格式指引的要求，编制了《2025 年半年度募集资金存放、管理与 实际使用情况的专项报告》。具体如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2020]1584 号"《关于同意成都苑东 生物制药股份有限公司首次公开发行股票注册的批复》同意注册，向社会公开发行 了人民币普通股（A 股）股票 3,009.00 万股，发行价为每股人民币 44.36 元，共计 募集资金总额为人民币 1,334,792,400.00 元，扣除发行费用（不含税）人民币 况业经中汇会计师事务所（特殊普通合伙）审验，并由其于 2020 年 8 月 26 日出具 了《验资报告》（中汇会验[2020] 5681 号）1。 （二） 募集金额使用情况和结余情况 截至 2025 年 6 月 30 日，结余募集资金（含利息收入扣除 ...

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has announced a two-year extension for the investment period of its "Drug Clinical Research Project" due to the actual progress of the project and to align with the company's long-term development strategy [1][4]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at a price of RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement has been signed with the sponsoring institution and the bank [1]. Investment Project Details - The company has adjusted the investment allocation for its fundraising projects, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary, Shod Pharmaceutical [2][3]. - The total investment for the "Drug Clinical Research Project" is RMB 11,400.00 million, with RMB 7,384.91 million already spent, indicating a progress rate of 64.78% [3]. Project Delay Specifics - The investment deadline for the "Drug Clinical Research Project" has been extended from September 2, 2025, to August 31, 2027, to accommodate additional clinical trials required for the project [3][4]. - The delay is attributed to the need for further clinical trials for the drug "Uroglitazone" to meet submission requirements for market approval [3][4]. Impact of Delay - The extension of the investment period is a prudent decision based on the project's actual implementation status and will not adversely affect the company's normal operations or the project's overall objectives [4][5]. - The board and supervisory committee have both approved the delay, confirming that it does not involve changes to the project's total investment, purpose, or scale [4][5].

苑东生物8月18日晚间发布公告称，公司第四届第七次董事会会议于2025年8月18日以现场和通讯相结合 的方式召开。会议审议了《关于的议案》等文件。 （文章来源：每日经济新闻） ...

中信证券股份有限公司 关于成都苑东生物制药股份有限公司 部分募集资金投资项目延期的核查意见 （二）募集资金投资项目情况 中信证券股份有限公司（以下简称"中信证券"）作为成都苑东生物制药股份 有限公司（以下简称"苑东生物"或"公司"）首次公开发行股票的保荐人，根据《证 券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律法规 和规范性文件的要求，对苑东生物部分募集资金投资项目延期事项进行了核查， 并出具核查意见如下： 根据公司《成都苑东生物制药股份有限公司首次公开发行股票并在科创板 上市招股说明书》披露的募集资金投资项目及募集资金使用计划，募集资金投资 项目情况如下： 一、募集资金基本情况 1 本核查意见中的募集资金净额 1,222,708,416.51 元与验资报告中的募集资金净额 1,222,700,659.41 元差异 7,757.10 元，系计划发行费用与实际存在差异：1.实际发行报告 制作费用较预计减少 9,433.93 元；2.实际印花税较预计增加 1,676.83 元。 1 公司于 2021 年 9 月 24 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-056 成都苑东生物制药股份有限公司 关于与关联方签署生产信息化系统相关协议暨 关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、关联交易概述 为了加快推进数字化、智能化在制药产业中的融合，实现药品生产数字化 智能管理，结合公司实际业务需要，公司于 2025 年 8 月 18 日召开第四届董事 会第七次会议审议通过《关于与关联方签署生产信息化系统相关协议暨关联交 易的议案》，公司全资子公司硕德药业拟向齐力佳采购生产信息化系统。硕德药 业拟就该事项与齐力佳签订《齐力佳智慧生产质量管理系统（IMMS）采购合 同》，合同金额 220 万元，合同期限为自协议签署之日起三年。 本次合作的对手方齐力佳由纪昌平先生实际控制，纪昌平先生系公司控股 股东、实际控制人及董事长王颖女士的妹夫。根据《上海证券交易所科创板股 票上市规则》的规定，纪昌平先生为公司的关联自然人，齐力佳为公司的关联 法人，本次交易构成关联交易。 过去 12 个月内公司与齐力 ...

成都苑东生物制药股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况的 专项报告 成都苑东生物制药股份有限公司（以下简称"苑东生物"、"本公司"或"公司"） 董事会根据《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规 范运作》及相关格式指引的要求，编制了《2025 年半年度募集资金存放、管理与 实际使用情况的专项报告》。具体如下： 一、募集资金基本情况 （一） 实际募集资金金额、资金到账时间 公司经中国证券监督管理委员会"证监许可[2020]1584 号"《关于同意成都苑东 生物制药股份有限公司首次公开发行股票注册的批复》同意注册，向社会公开发行 了人民币普通股（A 股）股票 3,009.00 万股，发行价为每股人民币 44.36 元，共计 募集资金总额为人民币 1,334,792,400.00 元，扣除发行费用（不含税）人民币 112,083,983.49 元，本次募集资金净额为 1,222,708,416.51 元。上述募集资金到位情 况业经中汇会计师事务所（特殊普通合伙）审验，并由其于 2020 年 8 月 26 日出具 了《验资报告》（中汇会验[2020] 5681 号） ...